Merck's Global Creative Review Covers 3 Drugs

Total media spending estimated at $50 million

The countdown to Brandweek is on! Join us, Sept. 12-16, to identify new growth opportunities, solve challenges and connect with power players. View the lineup and secure your pass.

The Merck & Co. consumer brands in play in the company’s global creative review are Dr. Scholl’s, Miralax and an incontinence drug for women that’s shifting from prescription to over-the-counter sales.
The company’s initial request for proposals doesn’t name the incontinence drug. Collective media spending on the business in review is estimated at $50 million.
Merck is seeking a second global agency to work along side Euro RSCG on its non-prescription consumer brands.

AW+

WORK SMARTER - LEARN, GROW AND BE INSPIRED.

Subscribe today!

To Read the Full Story Become an Adweek+ Subscriber

View Subscription Options

Already a member? Sign in